DAWN Stock Down -11% after 8-Day Loss Streak

DAWN: Day One Biopharmaceuticals logo
DAWN
Day One Biopharmaceuticals

Day One Biopharmaceuticals (DAWN) stock hit day 8 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -9.6% return. The company has lost about $64 Mil in valuation over the last 8 days, with its current market capitalization being $668 Mil. The stock remains 49.4% below its value at the end of 2024. This compares with year-to-date returns of 1.7% for the S&P 500 and -0.5% for the Trefis High Quality Portfolio.

Comparing DAWN Stock Returns With The S&P 500

The following table summarizes the return for DAWN stock vs. the S&P 500 index over different periods, including the current streak:

Return Period DAWN S&P 500
1D -1.4% -0.0%
8D (Current Streak) -10.8% -0.3%
1M (21D) -1.1% 0.3%
3M (63D) -22.6% 5.4%
YTD 2025 -49.4% 1.7%
2024 -13.2% 23.3%
2023 -32.2% 24.2%
2022 27.7% -19.4%

Gains and Losses Streaks: S&P 500 Constituents

There are currently 23 S&P constituents with 3 days or more of consecutive gains and 60 constituents with 3 days or more of consecutive losses.

Consecutive Days # of Gainers # of Losers
3D 17 11
4D 1 39
5D 2 2
6D 2 7
7D or more 1 1
Total >=3 D 23 60

Key Financials for Day One Biopharmaceuticals (DAWN)

Last 2 Fiscal Years:

Relevant Articles
  1. Why Is Merck Stock Still Undervalued After An 80% Surge?
  2. Figure’s Take Rate Is Shrinking By Design
  3. Make Your TDG Shares Pay You 9.8% A Year While You Hold Them
  4. The Options Market Puts PayPal Stock Between The High Forties And The High Seventies
  5. What Could Power The Next Rally In McDonald’s Stock
  6. What You Are Really Paying For In Arista Networks Stock

Metric FY2023 FY2024
Revenues $131.2 Mil
Operating Income $-206.1 Mil $-217.3 Mil
Net Income $-188.9 Mil $-95.5 Mil

Last 2 Fiscal Quarters:

Metric 2024 FQ4 2025 FQ1
Revenues $29.2 Mil $30.8 Mil
Operating Income $-65.3 Mil $-41.1 Mil
Net Income $-65.7 Mil $-36.0 Mil

The losing streak DAWN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.